[
  {
    "ts": "2025-09-23T22:18:36+00:00",
    "headline": "US FDA declines to approve higher dose of Biogen's genetic disorder drug",
    "summary": "(Reuters) -The U.S.",
    "url": "https://ca.finance.yahoo.com/news/us-fda-declines-approve-higher-221836161.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "fec2c9b6-888c-3ff3-a791-5e00fb30e299",
      "content": {
        "id": "fec2c9b6-888c-3ff3-a791-5e00fb30e299",
        "contentType": "STORY",
        "title": "US FDA declines to approve higher dose of Biogen's genetic disorder drug",
        "description": "",
        "summary": "(Reuters) -The U.S.",
        "pubDate": "2025-09-23T22:18:36Z",
        "displayTime": "2025-09-23T22:18:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/40c0c8656e40aa34c9e7eb3408a3ad71",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "FILE PHOTO: Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gX79LEF16O3R1oXpUPkk8A--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/40c0c8656e40aa34c9e7eb3408a3ad71.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aF_.13qofNcOY4qfiM.h0Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/40c0c8656e40aa34c9e7eb3408a3ad71.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/us-fda-declines-approve-higher-221836161.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-fda-declines-approve-higher-221836161.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T20:30:00+00:00",
    "headline": "Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen",
    "summary": "CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA. The letter did not",
    "url": "https://finance.yahoo.com/news/biogen-provides-regulatory-high-dose-203000028.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6f889058-8c10-3f23-a619-8314c83c8f80",
      "content": {
        "id": "6f889058-8c10-3f23-a619-8314c83c8f80",
        "contentType": "STORY",
        "title": "Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen",
        "description": "",
        "summary": "CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA. The letter did not",
        "pubDate": "2025-09-23T20:30:00Z",
        "displayTime": "2025-09-23T20:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-provides-regulatory-high-dose-203000028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-provides-regulatory-high-dose-203000028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IONS"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]